Brief communication: The current status of contrast-enhanced mammography in breast imaging.

Improvising and developing state of the art techniques for breast cancer detection have always been an area of great interest in the field of imaging. Adding intravenous contrast to any imaging study, is well-known to increase the sensitivity and specificity of detection of a pathological process, especially in the setting of neoplasia secondary to tumor neoangiogenesis. Contrast enhanced MRI is known to be highly sensitive breast cancer screening tool till date, however, has been limited by long scan times, claustrophobia experienced by some women and high false positive findings. Despite continued advances in digital mammography technique, significant limitations have always been experienced in detection of small cancers especially in the setting of dense breast parenchyma. Implementing dual energy subtraction technique to digital mammography, made contrast enhanced mammography a viable technique to improve cancer detection. We aim to discuss the status of contrast enhanced mammography in this brief communication, emphasizing technical background, image acquisition, clinical applications, and future directions.

State-of-the-art for contrast-enhanced mammography.

Contrast-enhanced mammography (CEM) is an emerging breast imaging technology with promise for breast cancer screening, diagnosis, and procedural guidance. However, best uses of CEM in comparison with other breast imaging modalities such as tomosynthesis, ultrasound, and MRI remain inconclusive in many clinical settings. This review article summarizes recent peer-reviewed literature, emphasizing retrospective reviews, prospective clinical trials, and meta-analyses published from 2020 to 2023. The intent of this article is to supplement prior comprehensive reviews and summarize the current state-of-the-art of CEM.

Pearls and Pitfalls of Contrast-Enhanced Mammography.

Contrast-enhanced mammography (CEM) is a promising new imaging modality that uses a dual-energy acquisition to provide both morphologic and vascular assessment of breast lesions. Although no official BI-RADS lexicon exists, interpretation entails using the mammographic BI-RADS lexicon in combination with that for breast MRI. CEM has comparable performance to breast MRI, with sensitivity of 93-100% and specificity of 80-94%. Currently FDA approved for diagnostic imaging, this technology can be helpful in determining disease extent in patients with newly diagnosed breast malignancy, monitoring response to neoadjuvant therapy, identifying mammographically occult malignancies, and diagnostic problem-solving. Studies are ongoing about its role in screening, especially in women with dense breasts or at elevated risk. There are some challenges to successful implementation into practice, but overall, patients tolerate the study well, and exam times are less than the full breast MRI protocol.